Caplin Point shares fall 6.45% despite a margin recovery
Consolidated profit grew 18.79% YoY, but a higher tax rate and other income contributing 14.89% of pre-tax profit shaped the quarter.
Filed 12 Aug 2026, 13:31 IST · Caplin Point Laboratories Ltd (CAPLIPOINT)
Key takeaways
- Consolidated net profit rose 18.79% YoY to Rs 179.09 cr, slower than the 22.10% increase in pre-tax profit as the tax rate rose 2.21 percentage points.
- Operating margin recovered 0.95 percentage points QoQ to 34.98% because revenue grew 1.70% while expenses increased only 0.24%.
- The stock fell 6.45% on the results day, a larger move than its 4.38% median absolute reaction after the past eight results.
Price around the results
Revenue growth stayed ahead of costs
Consolidated revenue grew 19.63% YoY, while expenses rose 19.38%, allowing operating profit to increase 20.09%. Sequential momentum was modest, with revenue up 1.70% QoQ, but the 0.24% rise in expenses supported a 4.52% increase in operating profit. Net profit rose 3.59% QoQ to Rs 179.09 cr.
Margin recovered, but profit quality needs context
Operating margin widened 0.14 percentage points YoY and 0.95 percentage points QoQ because costs did not grow faster than revenue. Other income accounted for 14.89% of pre-tax profit, so reported earnings were not entirely operating-led. The tax rate rose 2.21 percentage points YoY and 1.48 percentage points QoQ, which limited net-profit growth relative to pre-tax profit.
Margin rebounded after two quarters of decline
The margin had declined from 35.42% in Q2FY26 to 34.95% in Q3FY26 and 34.03% in Q4FY26 before recovering to 34.98% this quarter. Caplin Point's margin was 12.03 percentage points above the 22.95% median for 65 reported Healthcare peers. Management said it won $7 million of Central America tenders to be supplied over the next two quarters and $12 million of Chile tenders to be supplied over the next 18 months.
Expansion pipeline remains the main management message
Management said it plans to file more than 120 products in Mexico over the next 18 months and 18 oncology submission batches across LatAm, the US and Europe over the next 12 months. The company told analysts it plans 12 additional US launches in FY27, while the presentation said the Pondicherry facility is intended to expand existing capacities by over 2X. Management also said around 50% of its approximately Rs 1,000+ cr investment programme was nearing completion, with the balance to be incurred over the next two to three years.
Market reaction was unusually sharp for Caplin Point
The stock fell 6.45% on the results day, with volume at 4.47 times the reference level and a relative return of -6.30%. Its previous eight result-day reactions were evenly split between four rises and four falls, while the median absolute move was 4.38%, making this decline larger than its typical reaction.
Q1FY27 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹610 cr | ₹600 cr | +1.70% | +19.63% |
| Other income | ₹34 cr | ₹28 cr | +18.27% | +44.76% |
| Expenses | ₹397 cr | ₹396 cr | +0.24% | +19.38% |
| Operating profit | ₹213 cr | ₹204 cr | +4.52% | +20.09% |
| Operating margin (%) | 34.98% | 34.03% | — | — |
| Interest | ₹0 cr | ₹0 cr | -50.00% | +0.00% |
| Depreciation | ₹22 cr | ₹19 cr | +15.00% | +32.72% |
| Profit before tax | ₹225 cr | ₹213 cr | +5.52% | +22.10% |
| Tax | ₹46 cr | ₹41 cr | +13.73% | +36.88% |
| Net profit | ₹179 cr | ₹173 cr | +3.59% | +18.79% |
| EPS (₹) | ₹23.27 | ₹22.38 | +3.98% | +15.77% |
Operating margin of 34.98% compares with a Healthcare sector median of 22.95% across 65 peers that have reported Q1FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | -6.45% | -6.30% |
Volume on the results session was 4.47× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Caplin One Labs' oncology facility in Kakkalur completed its first regulatory inspection and submission batches for six products.
- Caplin received four additional product approvals in Mexico.
Guidance & outlook
- Caplin plans to file a pipeline of 120+ products in Mexico over the next 18 months.
- Caplin plans 18 oncology product submission batches in the next 12 months for LatAm, US and EU markets.
- Caplin aims to file its first DMFs from the Vizag API site in 2026/27.
- Caplin plans to launch 12 more products in the US during FY27.
Expansion
- The Pondicherry OSD and Dermatology facility is intended to more than double existing capacities.
- Amaris Clinical is being expanded to increase capacity to 120 beds, with completion expected by the end of FY27.
- Caplin has allocated approximately ₹1,000+ crore for investment projects, with the balance spent over the next two to three years.
New orders
- Caplin won $7 million of emergency tenders across Central America, to be supplied over the next two quarters.
- Caplin won $12 million of tenders in Chile, to be supplied over the next 18 months.
New products
- Caplin plans to launch the four newly approved Mexican products in the coming months.
New initiatives
- The Vizag API unit completed scale-up for six APIs for backward integration into US and Latin American formulations.
- Caplin plans to file its first pre-filled syringe product from the site in FY27, followed by 14+ filings in FY28.
What to watch
- Whether operating margin holds above 34.98% after the Q4FY26 trough of 34.03%.
- Whether other income remains near or below its 14.89% share of pre-tax profit.
- Progress on the $7 million Central America tenders scheduled for supply over the next two quarters.